Innovative BioTherapies, Inc. (IBT) is a privately held, for-profit company
founded in 2003 by Dr. H. David Humes, Professor of Medicine at the University of Michigan. IBT is a
recognized leader in extracorporeal blood circuit technologies, combining scientific excellence with
proven expertise in medical device development, clinical validation, and FDA regulatory pathways.
Leveraging its strong roots at the University of Michigan, IBT draws on
world-class academic research, clinical insight, and top-tier scientific talent to advance breakthrough
therapeutic platforms. The company’s unique integration of technological innovation, clinical experience,
and operational execution has been instrumental in developing multiple extracorporeal devices that have
demonstrated significant improvements in patient outcomes across diverse disease areas.
With a solid foundation in translational medicine and a track record of
successful innovation, IBT is well-positioned to expand its impact in the growing field of bioengineered
and extracorporeal therapies, delivering transformative solutions that address critical unmet medical
needs.
